Hisato Kawakami

讲师

Kindai University

关注

立即认领

关注

立即认领

基本信息

浏览量：65

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 243 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplemental Table 3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

Makoto Nishio,Shuji Murakami,Hisato Kawakami,Kyoichi Okishio,Motohiro Tamiya,Hiroyoshi Kobayashi,Daichi Fujimoto,Shunichi Sugawara,Toshiyuki Kozuki,Yuko Oya,Hiroki Izumi,Takayuki Shiroyama,Miyako Satouchi,Noboru Yamamoto,Shota Kaname,Daiko Matsuoka,Yohei Otake,Takao Takase,Taro Semba,Koichi Azuma

openalex

引用0浏览0引用

Different Efficacy of Tyrosine Kinase Inhibitors by KIT and PGFRA Mutations Identified in Circulating Tumor DNA for the Treatment of Refractory Gastrointestinal Stromal Tumors

Tadayoshi Hashimoto,Yoshiaki Nakamura,Yoshito Komatsu,Satoshi Yuki,Naoki Takahashi,Naohiro Okano,Hidekazu Hirano,Koushiro Ohtsubo,Takashi Ohta,Eiji Oki,Tomohiro Nishina,Hisateru Yasui,Hisato Kawakami,Taito Esaki,Nozomu Machida,Ayako Doi,Shogen Boku,Toshihiro Kudo,Yoshiyuki Yamamoto,Akiyoshi Kanazawa,Tadamichi Denda,Masahiro Goto,Naoko Iida, Hiroshi Ozaki,Taro Shibuki,Mitsuho Imai,Takao Fujisawa,Hideaki Bando,Yoichi Naito,Takayuki Yoshino

BJC reportsno. 1 (2024): 54-54

引用0浏览0WOSNATURE引用

Influence of Major Hepatectomy on Gemcitabine-Based Chemotherapy for Recurrent Biliary Tract Cancer after Surgery: a Subgroup Analysis of JCOG1113

Tatsuya Okuno,Chigusa Morizane,Junki Mizusawa,Hiroaki Yanagimoto,Satoshi Kobayashi,Hiroshi Imaoka,Takeshi Terashima,Hisato Kawakami,Yusuke Sano,Takuji Okusaka,Masafumi Ikeda,Masato Ozaka,Haruo Miwa,Akiko Todaka,Satoshi Shimizu,Nobumasa Mizuno,Mitsugu Sekimoto,Keiji Sano,Kazutoshi Tobimatsu,Akio Katanuma,Kunihito Gotoh,Hironori Yamaguchi,Hiroshi Ishii,Junji Furuse,Makoto Ueno

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2024)

引用0浏览0WOS引用

Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab As Second-Line Treatment for Metastatic Colorectal Cancer

Yu Sunakawa,Yasutoshi Kuboki,Jun Watanabe,Tetsuji Terazawa,Hisato Kawakami,Mitsuru Yokota,Masato Nakamura,Masahito Kotaka,Naotoshi Sugimoto,Hitoshi Ojima,Eiji Oki,Takeshi Kajiwara,Yoshiyuki Yamamoto,Yasushi Tsuji,Tadamichi Denda,Takao Tamura,Soichiro Ishihara,Hiroya Taniguchi,Takako Eguchi Nakajima,Satoshi Morita,Kuniaki Shirao,Naruhito Takenaka,Daisuke Ozawa,Takayuki Yoshino

Targeted Oncologyno. 1 (2024): 59-69

引用0浏览0WOS引用

QUATTRO-II Randomized Trial: CAPOXIRI+bevacizumab Vs. FOLFOXIRI+bevacizumab As First-Line Treatment in Patients with Mcrc

Hideaki Bando,Daisuke Kotani,Hironaga Satake,Tetsuya Hamaguchi,Manabu Shiozawa,Masahito Kotaka,Toshiki Masuishi,Hisateru Yasui,Yoshinori Kagawa,Yoshito Komatsu,Eiji Oki,Yoshiyuki Yamamoto,Hisato Kawakami,Toshihiro Misumi,Hiroya Taniguchi,Kentaro Yamazaki,Kei Muro,Takayuki Yoshino,Takeshi Kato,Akihito Tsuji

MEDno. 9 (2024)

引用0浏览0WOS引用

Predictive and Prognostic Value of Excision Repair Cross-Complementing Group 1 in Patients with Advanced Gastric Cancer

Yasuhide Yamada,Kengo Nagashima,Mizutomo Azuma,Mitsuko Masutani,Hitoshi Ichikawa,Satoru Iwasa,Naoki Takahashi,Hidekazu Hirano,Keisuke Kanato,Nozomu Machida,Takahiro Kinoshita,Hiroaki Hata,Hisato Kawakami,Daisuke Takahari,Narikazu Boku,Yukinori Kurokawa,Masanori Terashima,Takaki Yoshikawa,Shigeki Sekine,Nobuyoshi Hiraoka

BJC reportsno. 1 (2024): 18-18

引用0浏览0WOSNATURE引用

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

Makoto Nishio,Shuji Murakami,Hisato Kawakami,Kyoichi Okishio,Motohiro Tamiya,Haruki Kobayashi,Daichi Fujimoto,Shunichi Sugawara,Toshiyuki Kozuki,Yuko Oya,Hiroki Izumi,Takayuki Shiroyama,Miyako Satouchi,Noboru Yamamoto,Shota Kaname,Daiko Matsuoka,Yohei Otake,Takao Takase,Taro Semba,Koichi Azuma

Cancer research communicationsno. 1 (2024): 226-235

引用0浏览0WOS引用

Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Akihito Kawazoe,Noboru Yamamoto,Naotoshi Sugimoto,Hisato Kawakami,Takashi Oshima,Kensei Yamaguchi,Kaori Hino,Motohiro Hirao,Yukinori Kurokawa,Takeshi Kawakami,Masahiro Tsuda, Hiroki Hara,Shota Kaname,Daiko Matsuoka,Yohei Otake,Keisuke Yasuda,Takao Takase,Shuya Takashima,Taro Semba,Kei Muro

crossref（2024）

引用0浏览0引用

Supplemental Figure 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

Makoto Nishio,Shuji Murakami,Hisato Kawakami,Kyoichi Okishio,Motohiro Tamiya, Hiroyoshi Kobayashi,Daichi Fujimoto,Shunichi Sugawara,Toshiyuki Kozuki,Yuko Oya,Hiroki Izumi,Takayuki Shiroyama,Miyako Satouchi,Noboru Yamamoto,Shota Kaname,Daiko Matsuoka,Yohei Otake,Takao Takase,Taro Semba,Koichi Azuma

openalex（2024）

引用0浏览0引用

Subgroup Analyses of the Effect of Ramucirumab in Pretreatment with Immune Checkpoint Inhibitor in RINDBeRG: A Randomized Clinical Trial in Third- or Further-Line Treatment of Gastric Cancer

Ryohei Kawabata,Daisuke Sakai,Shigenori Kadowaki,Takao Tsuduki,Takahisa Suzuki,Toru Masuzawa,Keitaro Shimozaki,Masahiro Tsuda,Takeshi Yamada,Toshifumi Yamaguchi,Shugo Ueda,Yosuke Kito,Toshiharu Hirose,Tomono Kawase,Takashi Nomura,Kazuhiro Nishikawa,Hisato Kawakami,Toshio Shimokawa,Narikazu Boku,Taroh Satoh

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 339-339

引用0浏览0引用

加载更多

作者统计

#Papers: 243

#Citation: 3407

H-Index: 29

G-Index: 55

Sociability: 7

Diversity: 3

Activity: 171

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn